Sunovion Answers and Support

Sunovion Answers and Support

Need support? Ask Sunovion Answers for information about LONHALA MAGNAIR

Our Sunovion Answers team of support specialists can assist you and your patients with questions on insurance coverage, co-pay costs, and available resources. Specialists are available between 8 AM and 8 PM ET, Monday through Friday.


Outstanding Customer Service 


Outstanding Customer Service

The Sunovion Answers Contact Center has been recognized by J.D. Power for providing

"An Outstanding Customer Service Experience"

for the Live Phone Channel.

2017 Sunovion Answers Call Center Recognition


J.D. Power 2017 Certified Contact Center ProgramSM recognition is based on successful completion of an audit and exceeding a customer satisfaction benchmark through a survey of recent servicing interactions. For more information, visit

4 steps that help ensure patient support

Step 1: Write two LONHALA MAGNAIR prescriptions for patients

  • Write two prescriptions for patients
  • –   One for the Starter Kit
  • –   One for Refill Kit

Step 2: Within 24-48 hours, patients can pick up the LONHALA MAGNAIR starter kit at their pharmacy

  • Within 24–48 hours, the Starter Kit is available for patients to pick up at their pharmacy

Step 3: Participating pharmacies or Sunovion Answers trains patients how to use LONHALA MAGNAIR

  • Through participating pharmacies, patients will receive training in the pharmacy or over the phone
  • If patients use a nonparticipating pharmacy, they can call Sunovion Answers for over-the-phone training

Step 4: Sunovion Answers follows up with LONHALA MAGNAIR patients

  • Patients receive a follow-up call 5-7 days after picking up their Starter Kit
  • Patients receive a call approximately 21 days after every fill

Important Safety Information & Indication

Important Safety Information

LONHALA MAGNAIR is contraindicated in patients with a hypersensitivity to glycopyrrolate or to any of the ingredients.

LONHALA MAGNAIR should not be initiated in patients with acutely deteriorating or potentially life-threatening episodes of COPD or used as rescue therapy for acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

As with other inhaled medicines, LONHALA MAGNAIR can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with LONHALA MAGNAIR, it should be treated immediately with an inhaled, short-acting bronchodilator; LONHALA MAGNAIR should be discontinued immediately and alternative therapy instituted.

Immediate hypersensitivity reactions have been reported with LONHALA MAGNAIR. If signs occur, discontinue LONHALA MAGNAIR immediately and institute alternative therapy.

LONHALA MAGNAIR should be used with caution in patients with narrow-angle glaucoma and in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema) and of urinary retention (e.g., difficulty passing urine, painful urination), especially in patients with prostatic hyperplasia or bladder-neck obstruction. Patients should be instructed to consult a physician immediately should any of these signs or symptoms develop.

The most common adverse events reported in ≥2% of patients taking LONHALA MAGNAIR, and occurring more frequently than in patients taking placebo, were dyspnea (4.9% vs 3.0%) and urinary tract infection (2.1% vs 1.4%).

LONHALA solution is for oral inhalation only and should not be injected or swallowed. LONHALA vials should only be administered with MAGNAIR.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

For additional information, please see full Prescribing Information and Patient Information for LONHALA MAGNAIR at


LONHALA® MAGNAIR® (glycopyrrolate) is an anticholinergic indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.